Article
Medicine, Research & Experimental
Cristina Bouzas, Rosario Pastor, Silvia Garcia, Margalida Monserrat-Mesquida, Miguel Angel Martinez-Gonzalez., Jordi Salas-Salvado, Dolores Corella, Albert Goday, J. Alfredo Martinez, Angel M. Alonso-Gomez, Olga Fernandez-Barcelo, Jesus Vioque, Dora Romaguera, Jose Lopez-Miranda, Ramon Estruch, Francisco J. Tinahones, Jose Lapetra, Lluis Serra-Majema, Blanca Riquelme-Gallegop, Vicente Martin-Sanchez, Xavier Pinto, Miguel Delgado-Rodriguez, Pilar Matia, Josep Vidal, Jersy-Jair Cardenas-Salas, Lidia Daimiel, Emilio Ros, Estefania Toledo, Josep M. Manzanares, Inmaculada Gonzalez-Monge, Miguel-Angel Munoz, Diego Martinez-Urbistondo, Lucas Tojal-Sierra, Carlos Munoz-Bravoaf, Salvador Miralles-Gisbert, Marian Martin, Antonio Garcia-Rios, Sara Castro-Barquero, Jose Carlos Fernandez-Garcia, Jose Manuel Santos-Lozano, F. Javier Basterra-Gortari, Liliana Gutierrez-Carrasquilla, Patricia Guillem-Saiz, Alba Satorres, Itziar Abete, Carolina Sorto-Sanchez, Javier Diez-Espino, Nancy Babio, Montse Fito, Josep A. Tur
Summary: In a one-year study involving 6881 patients with MetS, it was found that those treated with GLP-1RA and DPP-4I had better glycemic profiles, but improvements in weight and waist circumference were modest.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Medicine, General & Internal
Michael Razavi, Ying-Ying Wei, Xiao-Quan Rao, Ji-Xin Zhong
Summary: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for type 2 diabetes mellitus, but their safety has been questioned.
MILITARY MEDICAL RESEARCH
(2022)
Article
Urology & Nephrology
Yang Xu, Edouard L. Fu, Catherine M. Clase, Faizan Mazhar, Meg J. Jardine, Juan J. Carrero
Summary: In this study, it was found that glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of kidney outcomes compared to dipeptidyl peptidase-4 inhibitors (DPP4i). The reductions in both kidney outcomes and major adverse cardiovascular events (MACE) were similar in magnitude to those reported in large cardiovascular outcome trials.
KIDNEY INTERNATIONAL
(2022)
Review
Clinical Neurology
Xiaocui Qin, Xia Zhang, Pinyu Li, Min Wang, Li Yan, Zeqing Bao, Qili Liu
Summary: The association between different oral diabetes medications and the risk of Parkinson's disease remains unclear. While the use of sulfonylureas, DPP4 inhibitors, metformin, and glitazones show no significant link to PD risk, metformin and glitazones may still increase the risk. Limited data suggests a protective effect of glucagon-like peptide-1 agonists on the risk of PD.
FRONTIERS IN NEUROLOGY
(2021)
Article
Endocrinology & Metabolism
Mona Mashayekhi, Jessica R. Wilson, Scott Jafarian-Kerman, Hui Nian, Chang Yu, Megan M. Shuey, James M. Luther, Nancy J. Brown
Summary: Genetic variation in the gene encoding the GLP-1 receptor may affect the metabolic response to DPP-4 inhibitors. The rs6923761 variant was associated with decreased postprandial glucose excursion in individuals with type 2 diabetes and hypertension. The study suggests a potential role of GLP1R rs6923761 genotype in modulating GLP-1 signaling in response to treatment.
DIABETES OBESITY & METABOLISM
(2021)
Article
Public, Environmental & Occupational Health
Richeek Pradhan, Elisabetta Patorno, Helen Tesfaye, Sebastian Schneeweiss, Hui Yin, Jessica Franklin, Ajinkya Pawar, Christina Santella, Oriana H. Y. Yu, Christel Renoux, Laurent Azoulay
Summary: The study compared GLP-1 receptor agonists users with different active comparator groups and found a modestly increased risk of anaphylactic reaction associated with GLP-1 RAs.
AMERICAN JOURNAL OF EPIDEMIOLOGY
(2022)
Review
Endocrinology & Metabolism
Samuel Igweokpala, Naheemot Olaoluwa Sule, Antonios Douros, Oriana H. Y. Yu, Kristian B. Filion
Summary: The use of incretin-based drugs is not associated with the risk of diabetic retinopathy among individuals with type 2 diabetes, according to the synthesis of available evidence from observational studies.
DIABETES OBESITY & METABOLISM
(2023)
Article
Chemistry, Medicinal
Baljit Kaur, Sombir Jaglan, Sudesh Rani, Yatin Batra, Palwinder Singh, Palwinder Vivesh
Summary: This study reports the design, synthesis, and biological studies of new anti-diabetic agents targeting DPP-4. The results show that 14 compounds display better inhibition activity against DPP-4 than the known drug Sitagliptin.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2022)
Article
Medicine, General & Internal
Hiroshi Nomoto, Sho Furusawa, Akinobu Nakamura, Jun Takeuchi, So Nagai, Hiroki Yokoyama, Ichiro Sakuma, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi
Summary: This multicentre trial aims to compare the effects of switching from a DPP-4 inhibitor to oral semaglutide on glycaemic control in patients with T2D. The study will assess the impact of oral semaglutide on HbA1c, body weight, abdominal circumference, blood pressure, and explore the relationship between improvement in metabolic parameters and patient background characteristics, side effects, and other laboratory parameters.
Review
Biochemistry & Molecular Biology
Aleksandra Pilszyk, Magdalena Niebrzydowska, Zuzanna Pilszyk, Magdalena Wierzchowska-Opoka, Zaneta Kimber-Trojnar
Summary: Gestational diabetes mellitus (GDM) is a metabolic disease affecting an increasing number of pregnant women worldwide. Controlling blood glucose levels is crucial to prevent complications. Current studies are investigating the use of other drug categories and have shown some success. These drugs may be used independently or as supplements to existing medications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Chemistry, Medicinal
Anand-Krishna Singh, Dhananjay Yadav, Neha Sharma, Jun-O Jin
Summary: Type 2 diabetes mellitus is characterized by high blood sugar levels, and therapeutic approaches include improving insulin sensitivity and using DPP-IV inhibitors. These inhibitors improve hyperglycemia by stabilizing gut hormones such as glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptides.
Article
Medicine, General & Internal
Mingtong Xu, Kan Sun, Wenjie Xu, Chuan Wang, Dewen Yan, Shu Li, Li Cong, Yinzhen Pi, Weihong Song, Qingyuan Sun, Rijun Xiao, Weixia Peng, Jianping Wang, Hui Peng, Yawei Zhang, Peng Duan, Meiying Zhang, Jianying Liu, Qingmei Huang, Xuefeng Li, Yan Bao, Tianshu Zeng, Kun Wang, Li Qin, Chaoming Wu, Chunying Deng, Chenghu Huang, Shuang Yan, Wei Zhang, Meizi Li, Li Sun, Yanjun Wang, Hongmei Li, Guang Wang, Shuguang Pang, Xianling Zheng, Haifang Wang, Fujun Wang, Xiuhai Su, Yujin Ma, Wei Zhang, Ziling Li, Zuoling Xie, Ning Xu, Lin Ni, Li Zhang, Xiangqun Deng, Tianrong Pan, Qijuan Dong, Xiaohong Wu, Xingping Shen, Xin Zhang, Qijing Zou, Chengxia Jiang, Jue Xi, Jianhua Ma, Jingchao Sun, Li Yan
Summary: The study aimed to evaluate the efficacy and safety of a novel DPP-4 inhibitor, fotagliptin, in treatment-naive patients with T2DM. The results demonstrated that fotagliptin was non-inferior to alogliptin in improving glycemic control, with significantly more patients in the fotagliptin and alogliptin groups achieving HbA1c < 7.0% after 24 weeks of treatment.
Review
Behavioral Sciences
Che-Yuan Wu, Lila Shapiro, Michael Ouk, Bradley J. MacIntosh, Sandra E. Black, Baiju R. Shah, Walter Swardfager
Summary: Type 2 diabetes is a major risk factor for dementia. Different glucose-lowering drugs have different effects on the brain. The current clinical and epidemiological data are mixed, requiring careful evaluation. Personalized strategies using glucose-lowering drugs have great potential in preventing and treating dementia.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2022)
Article
Gastroenterology & Hepatology
Santo Colosimo, Federico Ravaioli, Maria L. Petroni, Lucia Brodosi, Francesca Marchignoli, Francesca A. Barbanti, Anna S. Sasdelli, Giulio Marchesini, Loris Pironi
Summary: The study showed that GLP-1 receptor agonists and SGLT-2 inhibitors can improve biomarkers of steatosis and fibrosis, therefore slowing down the progression of liver disease.
LIVER INTERNATIONAL
(2021)
Review
Biochemistry & Molecular Biology
Teodor Salmen, Valeria-Anca Pietrosel, Bianca-Margareta Mihai, Ioana Cristina Bica, Claudiu Teodorescu, Horia Paunescu, Oana Andreia Coman, Doina-Andrada Mihai, Anca Pantea Stoian
Summary: The present study analysed published data on the use and pathogenesis of novel antidiabetic drugs in patients with type 2 diabetes and COVID-19. Limited evidence suggests that these drugs, including DPP-4i, GLP-1 Ra, and SGLT-2i, may have beneficial effects on glycemic control and inflammation in COVID-19 treatment, with overall favorable efficacy and safety profiles.